All In Biotech

Drug Trial Radar · NCT00175838

Primary Thrombocythaemia 1 Trial

A Randomised Trial to Compare Aspirin vs Hydroxyurea/Aspirin in 'Intermediate Risk' Primary Thrombocythaemia and Aspirin Only With Observation in 'Low Risk'Primary Thrombocythaemia

Last checked: Nov 19, 2026Latest source record: Jan 18, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 1,398 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,398

Actual

Start

Jul 1997

Primary completion

Nov 2016

Study completion Nov 2016

Sponsor

Lead sponsor
University of CambridgeAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Cambridge University Hospitals NHS Foundation Trust; Institute of Cancer Research, United Kingdom
First posted
Sep 15, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 40 years, up to 59 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this trial is to see if Hydroxyurea + aspirin is a better treatment than aspirin alone for Intermediate Risk Primary Thrombocythemia (PT) patients.

Conditions

  • Thrombocythemia
  • Myeloproliferative Disorder

Interventions

  • HydroxyureaDrug

    Hydroxyurea (or hydroxycarbamide) is an antineoplastic drug commonly used to treat haematological malignancies.

  • AspirinDrug

    Aspirin is an anti-aggregating agent, and has been shown to reduce/alleviate minor ischaemic symptoms.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Does hydroxyurea reduce thrombosis and major haemorrhage when added to aspirin?Time frame: 14 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Addenbrooke's Hospital

    Cambridge, Cambs, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.